Skip to main content

Table 1 Characteristics of clinical trials included in the analysis

From: Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials

TRIALSPHASEYEAR≥ 65 Yrs PATIENTS N.TREATMENT ARMSCOMBINATION ARM PATIENTS N.STANDARD ARM PATIENTS N.PFS HRCI
SWOGIII2012334Ful + Ana vs Ana1711730.79(0.62–1.01)
LEAIII2015189Bev + Let or Ful vs Let or Ful891000.82(0.64–1.06)
FACTIII2012245Ful + Ana vs Ana1341111.08(0.70–1.39)
HORIZONIII2013458Tem + Let vs Let2312271.21(0.92–1.59)
MONALEESA 2III2018295Ribo + Let vs Let1501450.61(0.39–0.94)
PALOMA 2III2016262Palbo + Let vs Let181810.57(0.39–0.84)
PALOMA 1 /TRIO-18II201476Palbo + Let vs Let37390.50(0.26–0.94)
MONARCH 3III2017222Abe + NSAI vs NSAI148740.57(0.36–0.90)
  1. Ful fulvestrant, Ana anastrozole, Bev bevacizumab, Let letrozole, Tem temsirolimus, Ribo ribociclib, Palbo palbociclib, Abe abemaciclib, NSAI non-steroidal aromatase inhibitor